Clinical Trial Update: CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on a Phase 1/Phase 2 clinical trial evaluating CD19 CAR-T cells in patients with relapse or refractory CD19-positive B-cell lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CD19 CAR T cells

Snippet

Sponsor: Shenzhen Second People's Hospital | Conditions: B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN